Project Grant R43AI192073
Award Date 8/21/26
Completion Date 7/31/27
Dollars Obligated $321K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Lebanon, NH 03766, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded Celdara Medical, LLC $320,863 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop precision chimeric antigen receptor (CAR) natural killer cell therapy targeting VK4-1-overexpressing autoreactive B cells in systemic lupus erythematosus. The Phase I SBIR project seeks to selectively remove disease-causing B cells while preserving non-pathogenic immune function, using humanized...
- The National Institute of Allergy and Infectious Diseases awarded the University of North Carolina at Charlotte $258,361 on August 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate innate immune stimulation through RIG-I activation for antibacterial responses against Staphylococcus aureus osteomyelitis. The project focuses on understanding how bone cells respond to S. aureus infection through pattern recognition receptors, particularly the cytosolic...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded University of North Carolina at Charlotte $402,284 under the Allergy and Infectious Diseases Research program (CFDA 93.855) on August 18, 2025, for a project extending through July 31, 2027. The project, titled "Augmenting Host Innate Immune Responses Against Staphylococcal Osteomyelitis with Antimicrobial Nucleic Acid Structures," focuses on developing novel treatment strategies to...
- The National Institute of Allergy and Infectious Diseases awarded The University of Texas MD Anderson Cancer Center $204,964 on June 8, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct proof-of-concept experiments evaluating nebulized pattern recognition receptor agonists (PAM2/ODN) as adjunctive immunomodulatory therapy against mold pneumonia in immunosuppressed hosts. The R21 phase of this R21/R33 project will generate preclinical data on the efficacy...
- The National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services, awarded $599,327 to Microbiotix, Inc. on September 22, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop novel benzyl-piperidine antifungal agents targeting intractable mucormycosis infections caused by drug-resistant Mucorales fungi. The project focuses on chemical optimization of a benzyl-piperidine series to improve drug-like properties and...
- The National Institute of Allergy and Infectious Diseases awarded Cmtx Biotech Inc. $296,470 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a novel liposomal formulation of rebamipide as an adjunctive host-directed treatment for Staphylococcus aureus bacteremia. Cmtx Biotech will conduct Phase I Small Business Technology Transfer research to address the high morbidity and mortality associated with S. aureus bloodstream infection, which...
- The National Institute of Allergy and Infectious Diseases awarded Vanderbilt University $105,216 on December 23, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the role of lipid-laden macrophages in Staphylococcus aureus osteomyelitis abscess formation. The research employs multimodal imaging techniques, including matrix-assisted laser desorption/ionization imaging mass spectrometry, to examine the spatial localization and physiology of...
- The National Institute of Allergy and Infectious Diseases, a component of the Department of Health and Human Services, awarded $148,614 to Massachusetts Institute of Technology on January 14, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The recipient will develop glycopolymers designed to enhance interactions between immune cells and pathogenic bacteria, creating "cellular glues" that leverage the body's innate immune mechanisms as an alternative to...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded $547,767 to the University of Rochester on June 1, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to investigate host mechanisms governing Staphylococcus aureus persistence during implant-associated osteomyelitis. The research uses humanized mouse models and multi-omic analysis of human T cells to understand why some patients resolve acute bone infections while others...
- The National Institute of Allergy and Infectious Diseases awarded the University of Massachusetts Medical School $251,250 on June 10, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop and characterize a novel mitochondrial-targeted inhibitor of NLRP3 inflammasome activation. The research addresses a critical gap in inflammasome therapeutics. While NLRP3 inflammasome activation drives pathogenesis in gout, atherosclerosis, type 2 diabetes, and Alzheimer's...